期刊文献+

费城染色体阴性骨髓增殖性肿瘤预后相关因素研究进展 被引量:1

原文传递
导出
摘要 费城染色体阴性(Ph-)的经典骨髓增殖性肿瘤(MPN)是一组恶性髓系肿瘤性疾病,主要包括原发性骨髓纤维化(PMF)、真性红细胞增多症(PV)和原发性血小板增多症(ET)。这组疾病临床过程通常较长,一般最终会进展至骨髓纤维化和急性白血病,其预后受血细胞计数升高、乳酸脱氢酶、基因突变等多种因素影响,中位生存期从几个月到几年不等。目前MPN常用的预后评估系统主要有IPSS、DIPSS,随着临床工作及科研进展,上述两种评分系统逐渐显现一些不足。本文总结了PMF、PV和ET三种疾病最新发现的临床、生物学、分子遗传学预后相关因素,并分析三种疾病预后因素中的相关性。
出处 《中国临床研究》 CAS 2020年第10期1414-1416,1421,共4页 Chinese Journal of Clinical Research
  • 相关文献

参考文献4

二级参考文献26

  • 1Chen E, Mullally A. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms? [J]. Hematology Am Soc Hematol Educ Program, 2014, 2014( 1 ):268-276.
  • 2Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders [J]. N Engl J Med, 2005, 352( 17):1779-1790.
  • 3Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies [ J 1~ Oncogene, 2013, 32 (21 ) :2601- 2613.
  • 4Chen E, Beer PA, Godfrey AL, et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling [J]. Cancer Cell, 2010, 18(5):524-535.
  • 5Chalign6 R, Tonetti C, Besancenot R, et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition [J]. Leukemia, 2008, 22 (8): 1557-1566.
  • 6Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2EJ~. N Engl J Med, 2013, 369(25):2391-2405.
  • 7Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms [J]. N Engl J Med, 2013, 369(25):2379-2390.
  • 8Vannucchi AM, mutationspeeific Rotunno G, Bartalucci N, et al. Calreticulin lmmunostalnmg neoplasms: pathogenetic insight Leukemia, 2014, 28(9):1811-1818 in myeloproliferative and diagnostic value EJ].
  • 9Geyer HL, Mesa RA.Therapy for myeloproliferative neoplasms: when, which agent, and how? [J]. Hematology Am Soe Hematol Educ Program, 2014, 2014( 1 ) :277-286.
  • 10Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes EJ]. Blood, 2014, 123( 10):1544-1551.

共引文献46

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部